Long-acting glp-1 compound

PT4086277TActive Publication Date: 2026-09-30GAN & LEE PHARM CO LTD
0 Cites 0 Cited by

Patent Information

Application Number
PT2020909624T
Authority / Receiving Office
PT · PT
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-09-29
Filing Date
2020-12-29
Publication Date
2026-09-30
Estimated Expiration
2040-12-29

AI Technical Summary

Technical Problem

Current GLP-1 compounds for treating diabetes have limitations in duration of action, potency, and side effect risk, and existing formulations of GLP-1 and insulin combinations face challenges in physical and chemical stability, necessitating the development of more effective and stable therapeutic agents.

Method used

A novel GLP-1 compound with specific structural modifications, including a fatty diacid substituent linked to the ε-amino group of the Lys residue, combined with an acylated insulin, is formulated to enhance stability and duration of action, allowing for less frequent dosing and improved efficacy.

Benefits of technology

The novel GLP-1 compound and combo formulation demonstrate improved physical and chemical stability, enabling subcutaneous treatment of diabetes patients with longer pharmacokinetic profiles, reduced side effects, and enhanced weight loss and diet suppression effects compared to existing drugs.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A novel GLP-1 derivative, compared with GLP-1 derivatives such as liraglutide and semaglutide which are on the market, has comparable or better effect, potency or efficacy, longer or comparable duration of action in vivo or half-life in vivo, has better or comparable GLP-1 receptor binding affinity and has better or comparable DPP-IV stability.
Need to check novelty before this filing date? Find Prior Art